Spandana Sphoorty appoints G. Parthasarathy as CRO, succeeding Anand, for three year term effective October 2025.
Natco Pharma USFDA Inspection Highlights
AXISCADES Secures Rs 152 Cr DRDO Deal
NSDL Stock Jumps 65% Post IPO
RateGain Powers Green Motion Growth
RBI Introduces STRIPS for State Government Securities
Astral Ltd. Financials: Mixed Results in FY25
Orchid Pharma Secures Full Rights to EXBLIFEP
News that matters the most ⚡